Harrow, Inc. (HROW)
(Delayed Data from NSDQ)
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 5:06 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.48 USD
+1.07 (1.90%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $57.47 -0.01 (-0.02%) 5:06 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow Health (HROW) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Harrow Health (HROW) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Harrow Health (HROW) stock based on the movements in the options market lately.
Harrow Health (HROW) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -2.27% and -4.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Harrow Health (HROW) Q3 Earnings Expected to Decline
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Air Industries, Chuy's, CNX Midstream Partners, Hibbett Sports and Harrow Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Air Industries, Chuy's, CNX Midstream Partners, Hibbett Sports and Harrow Health
5 Best Stocks to Buy on Dollar's Newfound Strength
by Tirthankar Chakraborty
Small caps, being U.S.-centric, are better poised to weather a stronger US dollar. This category is cushioned against the loss of competitiveness and impact of a stronger greenback.
Harrow Health Enters Oversold Territory
by Zacks Equity Research
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 7.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.